TCHP antibody
- Known as:
- TCHP (anti-)
- Catalog number:
- orb100712
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- TCHP antibody
Related genes to: TCHP antibody
- Gene:
- TCHP NIH gene
- Name:
- trichoplein keratin filament binding
- Previous symbol:
- -
- Synonyms:
- MGC10854, TpMs
- Chromosome:
- 12q24.11
- Locus Type:
- gene with protein product
- Date approved:
- 2006-01-27
- Date modifiied:
- 2016-03-14
Related products to: TCHP antibody
Related articles to: TCHP antibody
- Five base-stabilized beryllium Grignards of the type LBeBrY (L = IDipp (1,3-bis(dipropylphenyl)imidazol-2-ylidene), IPr (1,3-dipropyl-4,5-dimethylimidazol-2-ylidene), CDP (hexaphenylcarbodiphosphorane), Y = Dur (2,3,5,6-tetramethylphenyl = duryl); L = IPr, Y = Tchp (2,4,6,-tricyclohexylphenyl); L = CAAC (1-(2,6-dipropylphenyl)-2,2,4,4-tetramethylpyrrolydin-5-ylidene, Y = Tmp (2,6-tetramethylpyrrolidine)) were synthesized by salt metathesis from LBeBr or ligand exchange at (EtO)BeBrY. Single-crystal X-ray diffraction analyses show that the angle between the beryllium and carbon ligand planes depends mainly on L, varying from coplanar (L = CDP) to orthogonal (L = IDipp), via 50-70° for L = IPr. In contrast, (CAAC)BeBrDur and (CAAC)BeBrTmp display coplanar and near-orthogonal arrangements, respectively. Energy decomposition analysis in combination with natural orbitals for chemical valence (EDA-NOCV) calculations rationalize these trends as arising from a balance of steric repulsion, stabilizing London dispersion interactions between L and Y, and small but non-negligible BeBrY→L (L = carbene) or L→BeBrY (L = CDP) π-donation components. Reduction of LBeBrAr led to complex product mixtures, presumably owing to Schlenk-type equilibria as well as the formation of highly reactive [LBeY] and LBeHY intermediates involved in ligand decomposition reactions. Only the one-electron reduction of (CAAC)BeBrTmp afforded a stable linear [(CAAC)BeTmp] radical, which EPR spectroscopy and DFT calculations indicate is a CAAC- rather than a Be-centered radical. - Source: PubMed
Publication date: 2026/06/09
Czernetzki CorinnaArrowsmith MerleKroll ThomasGärtner AnnalenaKrummenacher IvoBraunschweig Holger - Few models exist for studying experimental therapeutics in inflammatory breast cancer (IBC). Our study objective was to characterize a novel patient-derived xenograft (PDX) from a HER2 positive IBC patient refractory to neoadjuvant chemotherapy. - Source: PubMed
Publication date: 2026/05/18
Ekpo PrincessKhattak MonicaCheung TiffanySu Yun YunBains Pushpinder KJuric IvanMakarov VladimirCampo DanielMcIntire PatrickRing AlexanderKrings GregorList KarinHicks JamesPress Michael FKeri RuthStanczyk MichaelSengupta GigiLang Julie E - Anthracycline-free neoadjuvant chemotherapy combined with dual HER2 blockade represents an alternative to anthracycline-containing regimens in early-stage HER2-positive breast cancer; however, real-world evidence remains limited. - Source: PubMed
Publication date: 2026/05/28
Buyukkuscu AsliIsleyen Zehra SucuogluEkinci Omer BurakAtasever TugayAkkaya KubraAydin OkanKulduk GamzeCelik EmirErturk KayhanAtci M Mustafa - Neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) is a widely used regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, achieving high rates of pathologic complete response (pCR). Taxane-induced peripheral neuropathy (CIPN) represents a clinically relevant dose-limiting toxicity that may lead to premature taxane discontinuation. Evidence guiding the optimal neoadjuvant strategy after CIPN onset remains limited in real-world, toxicity-driven treatment modification scenarios. - Source: PubMed
Publication date: 2026/04/14
Negreanu Răzvan AdrianVerga NicolaeGăinariu Estera - Three very bulky β-diketimine protio-ligands (NacnacH, {(Ar)N[double bond, length as m-dash]C(Bu )}CH, Ar = 2,4,6-tricyclohexylphenyl TCHP; 2,6-dicyclohexylphenyl DCHP; TCHP/Dip, Dip = 2,6-diisopropylphenyl) have been synthesised. These have been used to prepare monomeric, three-coordinate β-diketiminato magnesium iodide complexes, [(Nacnac)MgI] (Ar = TCHP 1, DCHP 3, or TCHP/Dip 5). Sodium metal reduction of 1 afforded the thermally robust anionic magnesium(0) complex [{(Nacnac)Mg}Na]6 in good yield. In contrast, reduction of less bulky [(Nacnac)MgI] 3 gave a mixture of unknown products, whilst reduction of [(Nacnac)MgI] 5 yielded the mixed oxidation state magnesium compound, [{(Nacnac)Mg}Mg] 7. The related compound [{(Nacnac)Mg}Mg] 8, was prepared by reduction of a 2 : 1 mixture of [(Nacnac)MgI] 1 and MgI. Computational analyses of 6 and 8 reveal their electronic structures to be comparable to those of previously reported analogues of these compounds. Reduction reactions between magnesium(0) compound 6 and the neutral groups 6 and 7 transition metal carbonyls, Cr(CO), Mo(CO) and Mn(CO), gave a series of complexes [{(Nacnac)Mg}{µ-M(CO) }] ( = 10, M = Cr 9 or Mo 10; = 8, M = Mn 11) which incorporate metal-metal single (9 and 10) or double (11) bonded metal carbonyl fragments. In contrast, reduction of Fe(CO) with 6 yielded [{(Nacnac)Mg}Na{Fe(CO)}]12 which does not possess an Fe-Fe bond, and can be viewed as an analogue of Collman's reagent, Na[Fe(CO)], in which one Na cation has been replaced by a [(Nacnac)Mg] unit. - Source: PubMed
Publication date: 2026/04/20
Jiang YixiaoNiksefat MaryamUnsworth Sophie GParr Joseph MEvans Matthew JJones Cameron